

Short communication

Dietary curcumin modulates phenobarbital- and acetone-induced CYP450 2B1 and 2E1 isozymes in mice

Garg R¹, Dolas S² and Maru GB²

¹Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

²Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, India.

Abstract

Curcumin pretreatment has been shown to inhibit benzo(a)pyrene-induced cytochrome P450 1A1/1A2 isozymes in liver and lungs of mice, via its modulatory effect on their transcriptional regulator, aryl hydrocarbon receptor. However, its effects on the activities of other CYP450 isozymes induced by carcinogen/promoter/solvent *in vivo* remain unknown. In the present study, we investigated the effect of curcumin on phenobarbital (PB)- and acetone-induced CYP2B1 and 2E1 isozymes respectively, *in vivo*. Dietary pretreatment of mice with chemopreventive doses of curcumin showed significant inhibition of PB-induced enzyme activity, protein and mRNA levels of CYP2B1 in mouse liver. Similarly, mice fed with curcumin in diet showed significant inhibition in the acetone-induced enzyme activity and protein levels of CYP2E1 in liver. However, no differences in the mRNA expression of CYP2E1 were observed in any of the treatment groups under consideration. Dietary curcumin alone also led to an increase in the activity of CYP2B1 and CYP2E1 though, it was marginal when compared to the effects induced by phenobarbital and acetone respectively. Overall, the results point towards a curcumin-mediated transcriptional regulation of PB-induced CYP2B1 and a posttranslational mechanism of regulation for acetone-induced CYP2E1 isozyme *in vivo*.

Keywords: Curcumin; Acetone; Phenobarbital; *In vivo*; Cytochrome P450.

Introduction

Turmeric and/or its main coloring component, curcumin (diferuloylmethane) have been shown to prevent chemical-induced tumors in several experimental systems [1-8]. Besides, the chemopreventive efficacy of turmeric/curcumin has been established at both initiation and promotion stages of carcinogenesis [8-14]. It has also been shown that turmeric/curcumin pre-treatment led to significant decreases in the levels of B(a)P/DMBA-derived DNA adducts in target and/or non-target tissues [11,15,16]. On the other hand, dietary treatment of mice with curcumin subsequent to B(a)P exposure was found to mediate disappearance of B(a)P-derived DNA adducts in both liver and lung tissues of mice [17]. Studies from our laboratory have demonstrated that dietary curcumin pre-treatment decreases B(a)P-induced cytochrome P450 1A1/1A2 (CYP1A1/1A2) via its modulatory effects on transcription regulator, aryl hydrocarbon receptor (AhR) [13,18]. However, it is yet not known if curcumin can also similarly modulate, *in vivo*, the carcinogen/promoter/solvent-induced activities of other members

of CYP450 family of isozymes. The present study therefore aims to investigate the effect(s) of curcumin on phenobarbital (PB)- and acetone-induced CYP2B1 and 2E1 isozymes, respectively in mice. Our findings demonstrate that dietary curcumin pre-treatment decreased the PB-induced enzyme activity, protein as well as mRNA expression of CYP2B1 in mouse liver. Moreover, we also show that curcumin pre-treatment decreased the acetone-induced activity and protein levels of CYP2E1 but did not alter its mRNA expression.

Methods

Materials

Curcumin, pentoxyresorufin and primers were obtained from Sigma Chemical Company (St Louis, MO). Antibodies for CYP2B1 and CYP2E1 were purchased from Novus Biologicals (Littleton, CO). ECL chemiluminescence detection kit was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Acetone (ultra pure analytical grade) was obtained from Merck Limited (Mumbai, India). Methanol was procured from S.D.Fine Chemicals Company (Mumbai, India).

Animal treatment

Inbred male Swiss albino mice (6-8 week old) were randomized into various treatment groups. Animals belonging to the 1st experimental set received drinking water ad libitum and were fed with either powdered standard laboratory diet (control diet) or experimental diet (0.01%/0.05% curcumin in standard laboratory diet), throughout the experimental duration of 18 days (Chart 1). Mice were given 10 mg/kg phenobarbital (PB) in 0.01% DMSO, i.p.


***Corresponding author:** Garg R, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Phone: (215)-898-1472; fax: (215)-746-8941; E-mail: rachanag@mail.med.upenn.edu

Rec Date: July 7, 2015, **Acc Date:** July 23, 2015, **Pub Date:** July 25, 2015.

Citation: Garg R, Dolas S, Maru GB (2015) Dietary curcumin modulates phenobarbital- and acetone-induced CYP450 2B1 and 2E1 isozymes in mice. BAOJ Cancer Res Ther 1: 005.

Copyright: © 2015 Garg R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

or 0.01% DMSO alone as vehicle, once a day during 15th-17th day of experiment. Amongst the various doses tried (10-80 mg/kg), relatively lower dose i.e. 10 mg/kg was selected for the induction of CYP2B1. Animals belonging to the 2nd set of experiment received control or experimental diet (0.01%/0.05% curcumin in diet) for the entire experimental period of 23 days and were given distilled water (vehicle control) or 1% acetone (v/v, made in distilled water) as the sole source of drinking water, during 15th-22nd day as reported [19]. Animals were sacrificed 24 h after the last PB/acetone treatment; their liver lobes were perfused, excised, and stored at -80°C until further use (Chart 1). Animals were weighed once in a week, their initial and final body weights and liver to body weight ratio were also recorded.



CYP2B1 Enzyme Activity

The activity of CYP2B1 isozyme was measured using specific probe drug as described [20]. Briefly, 1 mg microsomal protein was incubated for 5 min at 37°C in a 0.1 M sodium phosphate buffer, pH 7.4 with 5 μM pentoxoresorufin, 6.25 mM MgSO₄, 60 μM EDTA in a final volume of 1 ml. Reaction was initiated by adding NADPH (250 μM), incubated for 5 min at 37°C and subsequently terminated by the addition of 2 ml ice-cold methanol. After centrifugation (4000 g, 5 min) to pellet the precipitated microsomal protein, the metabolite resorufin was measured by spectrofluorometry (Ex= 550 nm and Em= 585 nm). Reaction mixture without NADPH served as the blank. Resorufin formed in the test samples was calculated from the standard curve plotted with 0-5 μM of resorufin under identical experimental conditions. Results were expressed as nmoles resorufin formed /min/mg protein.

CYP2E1 Enzyme Activity

The CYP2E1 activity was measured in liver microsomes by HPLC determination of the hydroxylation of p-nitrophenol as described with some modifications [21]. Briefly, 1 mg microsomal protein

was incubated in 50 mM Tris buffer pH 7.4, 5 mM MgCl₂, 1.5 mM NADPH in a final volume of 500 μl at 37°C for 5 min. Reaction was initiated by the addition of p-nitrophenol (100 μM), incubated for an additional 20 min at 37°C before termination with 25 μl trifluoroacetic acid (99% pure). The amount of p-nitrocatechol formed was measured in the supernatants using Waters HPLC system consisting of dual pumps and a UV-Vis detector, at 345 nm. Samples were analyzed with a C18 reverse-phase column (250 x 4.6 mm) and eluted at a flow rate of 1.5 ml/min, with mobile phase comprising of 52.8% acetonitrile, 1% tri-fluoroacetic acid in distilled water, pH 2.5. A standard curve prepared with 0.025-0.5 ng/ml p-nitrocatechol was used for quantitating p-nitrocatechol in the sample, as the measure of CYP2E1 activity. Results were expressed as nmol p-nitrocatechol formed/min/mg protein.

Protein Immunoblotting

50 μg microsomal proteins were separated on a 12% SDS polyacrylamide gel as described earlier [13] and immunoblotted using polyclonal antibodies for CYP2B1/2E1 (1:10,000 dilutions). In the absence of a well accepted standard internal control for microsomal proteins, quantitative analysis was done by normalizing the CYP2B1/2E1 immunoblot with a prominent band visualized on membrane after Ponceau-S staining, as has also been done before [13].

RNA Isolation and Semiquantitative RT-PCR

Total RNA from mouse liver tissue was isolated and reverse transcribed to cDNA as previously described [13]. The resulting cDNAs were subjected to PCR using specific primer sequences for CYP2B9 (mouse ortholog of rat CYP2B1), CYP2E1, and GAPDH (house keeping gene), and amplification conditions as detailed in Table 1 and 2. PCR products were then, electrophorized on 1.8% agarose gel and visualized after ethidium bromide staining.

Table 1. Oligonucleotide sequences used in RT-PCR:

| Gene | Forward primer (5'–3') | Reverse primer (5'–3') | Product (bp) |
|--------|------------------------|------------------------|--------------|
| CYP2B9 | TGAAGCTTTTCTGCCCTCT | GTGTGAGCAGCTACCAATGG | 311 |
| CYP2E1 | CTGATTGGCTGCGACCCTGC | GAACAGGTCGGCCAAAGTCAC | 381 |
| GAPDH | CCTCTGGAAGCTGTGGCGT | TTGGAGCCATGTAGGCCAT | 431 |

Table 2. Amplification conditions employed in RT-PCR analysis:

| Gene | Annealing temperature, time | No. of cycles | Reference |
|--------|-----------------------------|---------------|--------------------|
| CYP2B9 | 53°C, 30 sec | 30 | Damon et al., 1996 |
| CYP2E1 | 67°C, 60 sec | 35 | Wahl et al., 2007 |

Results

Based on the body weight (Table 3 and 4), liver weight, or liver to body weight ratio, no toxicity was observed in animals belonging to the various treatment groups. However, mild histological changes in liver tissue architecture (focal necrosis, spongy appearance) were observed in all animals.

Table 3. Body weights of mice belonging to phenobarbital experimental set 1

| Groups (1 st set) | Initial body weights in grams (g) (Mean ± SE) | Final body weights in grams (g) (Mean ± SE) |
|------------------------------|---|---|
| VC | 21.83 ± 3.92 | 24.12 ± 3.03 |
| PB | 22.45 ± 2.68 | 25.03 ± 2.65 |
| 0.01%C + PB | 22.49 ± 3.8 | 24.94 ± 4.6 |
| 0.05%C | 24.01 ± 3.64 | 26.83 ± 4.47 |
| 0.05%C + PB | 23.83 ± 3.88 | 26.07 ± 2.57 |

Table 4. Body weights of mice belonging to acetone experimental set 2

| Groups (2 nd set) | Initial body weights in gram (g) (Mean ± SE) | Final body weights in grams (g) (Mean ± SE) |
|------------------------------|--|---|
| VC | 23.78 ± 3.87 | 26.09 ± 3.92 |
| Ace | 24.87 ± 4.01 | 27.17 ± 2.76 |
| 0.01%C + Ace | 24.45 ± 3.76 | 27.87 ± 4.12 |
| 0.05%C | 23.56 ± 3.78 | 26.31 ± 3.76 |
| 0.05%C + Ace | 23.96 ± 4.76 | 26.71 ± 4.75 |

Curcumin Pre-treatment Decreases PB/acetone-induced Activity of CYP2B1/2E1

It was observed that mice fed with control diet and receiving 10 mg/kg phenobarbital (PB), i.p., showed significant induction of CYP2B1 enzyme activity (Figure 1A) and those that received 1% acetone in drinking water showed significant induction of CYP2E1 enzyme activity in liver tissue (Figure 1B) as compared to the basal activity observed in respective vehicle treated control animals. 0.05% dietary curcumin alone also significantly increased CYP2B1 and CYP2E1 activity though; it was significantly less when compared to the induction mediated by phenobarbital/acetone treatment. However, dietary curcumin (0.01%/0.05%) pre-treatment significantly decreased the PB-induced CYP2B1 activity (26-32%) measured as the dealkylation of PR (Figure 1A) as well as that of the acetone-induced CYP2E1 activity (12-39%, Figure 1B), measured as the hydroxylation of p-nitrophenol (Figure 2).




Figure 1. (A) Effect of curcumin pre-treatment on phenobarbital-induced CYP2B1 enzyme activity in mouse liver microsomes. Enzyme activity was expressed as nmol of resorufin formed/min/mg protein. Data represent mean ± SE of six observations. * = significantly different from VC; £ = significantly different from PB; § = significantly different from 0.05%C ($p \leq 0.05$, ANOVA followed by Bonferroni Test). (B) Effect of curcumin pre-treatment on acetone-induced CYP2E1 enzyme activity in mouse liver microsomes. Enzyme activity was expressed as nmol of p-nitrocatechol formed/min/mg protein. Data represent mean ± SE of six observations. * = significantly different from VC; § = significantly different from Ace; † = significantly different from 0.05% C + BP ($p \leq 0.05$, ANOVA followed by Bonferroni Test).




Figure 2. Typical HPLC chromatogram showing the separation of p-nitrophenol, p-nitrocatechol and NADPH.

Curcumin Pre-treatment Decreases PB/acetone-induced protein levels of CYP2B1/2E1

Next, it was determined if the observed curcumin-mediated decrease in PB-induced CYP2B1 activity and acetone-induced CYP2E1 activity was due to the altered levels of proteins. Basal protein

expression of CYP2B1/2E1 was detected in liver of vehicle treated control animals. As compared to the respective vehicle treated control animals, CYP2B1 protein expression was significantly increased in PB treated animals (Figure 3A) and that of CYP2E1 in acetone treated animals (Figure 3B). 0.05% dietary curcumin alone also significantly increased the CYP2B1 and CYP2E1 protein levels. Notably, as observed with the enzyme activity, pre-treatment with dietary curcumin (0.01%/0.05%) significantly decreased the PB-induced CYP2B1 (21-32%) and acetone-induced CYP2E1 (11-40%) protein expression in mouse liver (Figure 3A and B).

Curcumin Pre-treatment Decreases PB-induced mRNA levels of CYP2B1 but did not Affect CYP2E1 mRNA Expression

Furthermore, the analysis of mRNA profile revealed that PB treatment significantly increased the mRNA expression of CYP2B9 (mouse ortholog of rat CYP2B1) compared to vehicle treated control animals (Figure 4A). Of note, dietary curcumin (0.01%/0.05%) pre-treatment significantly reduced the PB-induced CYP2B9 (33-62%) mRNA level. However, the mRNA level of CYP2E1 remained unaltered in animals belonging to the various treatment groups (Figure 4B).




Figure 3. (A) Effect of curcumin pre-treatment on phenobarbital-induced CYP2B1 protein levels analyzed by immunoblotting. Representative blot and quantitation data presented as mean \pm SE of six observations. * = significantly different from VC; £ = significantly different from PB; \$ = significantly different from 0.05% C ($p \leq 0.05$, ANOVA followed by Bonferroni Test). (B) Effect of curcumin pre-treatment on acetone-induced CYP2E1 protein levels analyzed by immunoblotting. Representative blot and quantitation data presented as mean \pm SE of six observations. Quantitative analysis was done by normalising the CYP2B1/2E1 immunoblot with a prominent band visualized on membrane after Ponceau-S staining. * = significantly different from VC; £ = significantly different from Ace; \$ = significantly different from 0.05% C; ‡ = significantly different from 0.05% C + Ace ($p \leq 0.05$, ANOVA followed by Bonferroni Test).




Figure 4. Effect of curcumin pre-treatment on (A) phenobarbital-induced CYP2B1 and (B) acetone-induced CYP2E1 mRNA levels analyzed by RT-PCR. Representative gel pictures and quantitation data presented as mean \pm SE of six observations. * = significantly different from VC; £ = significantly different from PB; ‡ = significantly different from 0.05% C + PB ($p \leq 0.05$, ANOVA followed by Bonferroni Test).

Discussion

Earlier observations have demonstrated that curcumin regulates B(a)P-induced CYP1A1/1A2 via their transcriptional regulator, AhR [13,22]. In the present study, we demonstrate that dietary curcumin decreased PB-induced CYP2B1 enzyme activity in mouse liver as reported in rats by 1% turmeric [18]. Additionally, the study demonstrates that the observed decrease in activity is due to curcumin-mediated decrease in PB-induced protein as well as mRNA levels of CYP2B1 *in vivo*. These observations thus indicate towards a transcriptional regulation of PB-induced CYP2B1 by curcumin *in vivo*. The induction of CYP2B1 by phenobarbital (PB) and PB-like inducers (e.g. chlorpromazine, phenytoin, clofibric acid and polychlorinated biphenyls) has been shown to be mediated by the orphan nuclear receptor, constitutive androstane receptor (CAR) [23-25] and for optimal expression, requires steroid co-activator 1 (SRC-1) and transcription factor, SP1 [26]. It will be interesting to determine if curcumin could modulate CAR to exert its effect on PB-induced CYP2B1 and warrants further investigation.

Our demonstration of increase in CYP2E1 protein content and enzyme activity upon acetone treatment is consistent with other reports [19,27]. Of note, we report here for the first time that dietary curcumin treatment decreases acetone-mediated induction of CYP2E1 at both activity and protein level in mouse liver. However, these alterations in CYP2E1 activity and protein level were not reflected in the mRNA expression. Acetone has been documented to induce CYP2E1 activity and protein content without altering mRNA levels [27,28]. Our results thus clearly suggest that curcumin regulates CYP2E1 via a posttranslational mechanism in mouse liver. However, further investigation into the mechanism is needed to establish if the observed curcumin-mediated changes in acetone-induced CYP2E1 protein are due to the effects on protein synthesis or protein stabilization.

It is to be noted that dietary curcumin (0.05%) alone although did not alter the basal activity/protein expression of CYP1A1/1A2 [13,18], it increased the CYP2B1/2E1 activity and protein level in mouse liver. It is therefore also desirable to understand the modulatory effect of curcumin on the transcriptional/translational regulation of these CYP450 isozymes. In the present study, only higher dose of curcumin has been employed as curcumin control, inclusion of the lower (0.01%) dose would have been beneficial in ascertaining a dose-dependent and further protective effect of curcumin.

Studies from our lab and others have shown that dietary turmeric/curcumin inhibit nitrosodiethylamine-induced hepatocarcinogenesis in mice/rats [4,29]. The oxidative bio-activation of nitrosamines is known to be mediated by CYP2B1/2E1 isozymes. Thus, the observed modulatory effects of curcumin on CYP2B1/2E1 isozymes is likely to play an important role in decreasing the generation of DNA reactive species in N-nitrosamines associated hepatocellular carcinogenesis.

Acknowledgements

Authors thank Mr. Prasad Phase and Mr. M. Jagtap for technical assistance.

Funding: R.G. is supported by a post-doctoral grant from the United States Department of Defense W81XWH-12-1-0009.

References

1. Azuine MA, Bhid SV (1992) Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. *Nutr Cancer* 17(1): 77-83.
2. Deshpande SS, Ingle AD, Maru GB (1997) Inhibitory effects of curcumin-free aqueous turmeric extract on benzo[a]pyrene-induced forestomach papillomas in mice. *Cancer Lett* 118(1): 79-85.
3. Deshpande SS, Ingle AD, Maru GB (1998) Chemopreventive efficacy of curcumin-free aqueous turmeric extract in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorigenesis. *Cancer Lett* 123(1): 35-40.
4. Thapliyal R, Naresh KN, Rao KV, Maru GB (2003) Inhibition of nitrosodiethylamine-induced hepatocarcinogenesis by dietary turmeric in rats. *Toxicol Lett* 139(1): 45-54.
5. Garg R, Ingle AD, Maru GB (2008b) Dietary turmeric modulates DMBA-induced p21^{ras}, MAP kinases and AP-1/NF- κ B pathway to alter cellular responses during hamster buccal pouch carcinogenesis *Toxicol. Appl. Pharmacol* 232(3): 428-439.
6. Gupta SC, Kismali G, Aggarwal BB (2013) Curcumin, a component of turmeric: from farm to pharmacy. *BioFactors* 39(1): 2-13.
7. Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran SA (2011) Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth *in vitro* and *in vivo*. *BMC Cancer* 11: 144.
8. Maru GB, Ramchandani AG, Kumar G, Garg R (2010) Curcumin-mediated cellular responses in chemical carcinogenesis: *In vivo* studies. In: Watson RR, Preedy VR (eds). *Bioactive Foods and Extracts: Cancer Treatment and Prevention*. CRC Press: 181-204.
9. Huang MT, Smart RC, Wong CQ, Conney A H (1988) Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. *Cancer Res* 48(21): 5941-5946.
10. Singh SV, Hu X, Srivastava SK, Singh M, Xia H, et al. (1998) Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. *Carcinogenesis* 19(8): 1357-1360.
11. Thapliyal R, Deshpande SS, Maru GB (2002) Mechanism(s) of turmeric-mediated protective effects against benzo(a)pyrene-derived DNA adducts. *Cancer Lett* 175(1): 79-88.
12. Chun KS, Keum YS, Han SS, Song YS, Kim SH, et al. (2003) Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF- κ B activation. *Carcinogenesis* 24(9): 1515-1524.
13. Garg R, Gupta S, Maru GB (2008a) Dietary curcumin modulates transcriptional regulator(s) of phase I and phase II enzymes in benzo(a)pyrene-treated mice: mechanism of its anti-initiating action. *Carcinogenesis* 29(5): 1022-1032.

14. Garg R, Ramchandani A, Maru GB (2008) Curcumin decreases 12-o-tetradecanoylphorbol-13-acetate-induced protein kinase C translocation to modulate downstream targets in mouse skin. *Carcinogenesis* 29(6): 1249-1257.
15. Mukundan MA, Chacko MC, Annapurna VV, Krishnaswamy K (1993) Effect of turmeric and curcumin on BP-DNA adducts. *Carcinogenesis* 14(3): 493-496.
16. Singletary K, MacDonald C, Wallig M, Fisher C (1996) Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. *Cancer Lett.* 103(2): 137-141.
17. Garg R, Maru G (2009) Dietary curcumin enhances benzo(a)pyrene-induced apoptosis resulting in a decrease in BPDE-DNA adducts in mice. *J. Environ. Pathol. Toxicol Oncol* 28(2): 121-131.
18. Thapliyal R, Maru GB (2001) Inhibition of cytochrome P450 isozymes by curcumins *in vitro* and *in vivo*. *Food Chem Toxicol* 39: 541-547.
19. Forkert PG, Redza ZM, Mangos S, Park SS, Tam SP (1994) Induction and regulation of CYP2E1 in murine liver after acute and chronic acetone administration. *Drug Metab Dispos* 22(2): 248-253.
20. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. *Biochem Pharmacol* 34(18): 3337-3345.
21. Duescher RJ, Elfarra AA (1993) Determination of p-nitrophenol hydroxylase activity of rat liver microsomes by high-pressure liquid chromatography. *Anal Biochem* 212(2), 311-314.
22. Powell JB, Ghotbaddini M (2014) Cancer-promoting and Inhibiting Effects of Dietary Compounds: Role of the Aryl Hydrocarbon Receptor (AhR). *Biochem Pharmacol* 3 (1): doi: 10.4172/2167-0501.1000131.
23. Swales K, Negishi M (2004) CAR, driving into the future. *Mol. Endocrinol.* 18, 1589-1598.
24. Ibrahim ZS, Ahmed MM, El-Shazly SA, Ishizuka M, Fujita S (2014). Clofibric acid induces hepatic CYP 2B1/2 via constitutive androstane receptor not via peroxisome proliferator activated receptor alpha in rat. *Biosci. Biotech Biochem* 78(9): 1550-1559.
25. Schraplau A, Schewe B, Neuschafer-Rube F, Ringel S, Neuber C, et al. (2015) Enhanced thyroid hormone breakdown in hepatocytes by mutual induction of the constitutive androstane receptor (CAR, NR1I3) and arylhydrocarbon receptor by benzo[a]pyrene and phenobarbital. *Toxicology* 328: 21-28.
26. Muangmoonchai R, Smirlis D, Wong SC, Edwards M, Phillips IR, et al. (2001) Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. *Biochem J* 355: 71-78.
27. Goasduff T, Bellec G, Amet Y, Dreano Y, Menez JF, et al. (1996) P450 2E1 expression in liver, kidney, and lung of rats treated with single or combined inducers. *Alcohol* 13(3): 301-308.
28. Carlson GP, Day BJ (1992) Induction by pyridine of cytochrome P450IIE1 and xenobiotic metabolism in rat lung and liver. *Pharmacology* 44(3): 117-123.
29. Chuang SE, Cheng A L, Lin JK, Kuo ML (2000) Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. *Food Chem Toxicol* 38(11): 991-995.